Flaws in design, analysis and interpretation of Pfizer's antifungal trials of voriconazole and uncritical subsequent quotations by Jørgensen, Karsten J et al.
BioMed  Central
Page 1 of 4
(page number not for citation purposes)
Trials
Open Access Commentary
Flaws in design, analysis and interpretation of Pfizer's antifungal 
trials of voriconazole and uncritical subsequent quotations
Karsten J Jørgensen1, Helle Krogh Johansen1,2 and Peter C Gøtzsche*1
Address: 1The Nordic Cochrane Centre, Rigshospitalet, Copenhagen, Denmark and 2Institute of Medical Microbiology and Immunology, 
University of Copenhagen, Denmark
Email: Karsten J Jørgensen - kj@cochrane.dk; Helle Krogh Johansen - hkj@cochrane.dk; Peter C Gøtzsche* - pcg@cochrane.dk
* Corresponding author    
Abstract
We have previously described how a series of trials sponsored by Pfizer of its antifungal drug,
fluconazole, in cancer patients with neutropenia handicapped the control drug, amphotericin B, by
flaws in design and analysis. We describe similar problems in two pivotal trials of Pfizer's new
antifungal agent, voriconazole, published in a prestigious journal. In a non-inferiority trial,
voriconazole was significantly inferior to liposomal amphothericin B, but the authors concluded
that voriconazole was a suitable alternative. The second trial used amphothericin B deoxycholate
as comparator, but handicapped the drug by not requiring pre-medication to reduce infusion-
related toxicity or substitution with electrolytes and fluid to reduce nephrotoxicity, although the
planned duration of treatment was 84 days. Voriconazole was given for 77 days on average, but the
comparator for only 10 days, which precludes a meaningful comparison.
In a random sample of 50 references to these trials, we found that the unwarranted conclusions
were mostly uncritically propagated. It was particularly surprising that relevant criticism raised by
the FDA related to the first trial was only quoted once, and that none of the articles noted the
obvious flaws in the design of the second trial.
We suggest that editors ensure that the abstract reflects fairly on the remainder of the paper, and
that journals do not impose any time limit for accepting letters that point out serious weaknesses
in a study that have not been noted before.
Introduction
The antifungal agent amphotericin B is a highly effective
drug [1,2] that is often used as comparator in trials of new
antifungal drugs. We have previously described how a
series of trials sponsored by Pfizer of its antifungal drug,
fluconazole, in cancer patients with neutropenia handi-
capped the control drug, amphotericin B, by flaws in
design and analysis [3]. Amphotericin B is usually given
intravenously [1,2], but most of the patients in Pfizer's tri-
als were randomized to oral amphotericin B, which is
poorly absorbed and not an established treatment.
Three of these trials were large and comprised 43% of the
patients that were available for our meta-analysis of
amphotericin B versus fluconazole [3]. In these trials,
patients had been randomised to three arms, the third
drug being nystatin, but the results for amphotericin B
were combined with the results for nystatin. This is sur-
prising, since this drug is recognized as ineffective in these
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circumstances, which we confirmed in a separate meta-
analysis of trials with nystatin [3]. Despite repeated
requests, neither the trial authors nor Pfizer provided us
with separate data for each of the three arms in these stud-
ies.
Flaws in trials of voriconazole
We now report problems with the design and analysis of
Pfizer's trials on its new antifungal agent, voriconazole.
We identified two eligible trials for our systematic review
of voriconazole [4]. They were both large, sponsored by
Pfizer, and published in The New England Journal of Medi-
cine in 2002 [5,6]. As with our previous review [3], the first
authors declined or were unable to answer our questions
and referred to Pfizer, which in this case provided a
response.
The first trial was a non-inferiority trial that compared vor-
iconazole to liposomal amphothericin B as empirical
treatment of fever of unknown origin in neutropenic can-
cer patients, using a composite endpoint with 5 separate
outcomes [5]. Voriconazole was inferior to liposomal
amphothericin B according to the authors' pre-specified
criteria, and even significantly inferior according to the pre-
specified analysis plan, which staff at the FDA pointed out
in a subsequent letter to the journal [7]. More patients
died in the voriconazole group and a claimed significant
reduction in so-called "breakthrough" fungal infections in
favour of voriconazole disappeared when infections arbi-
trarily excluded from analysis were included. The authors
defined breakthrough fungal infections as those con-
firmed more than 24 hours post-enrolment. The reason
for a 24-hour cut-point to exclude baseline fungal infec-
tions from analysis was not explained. We searched the
references provided as justification for this cut-point in
the article but could not find any relevant information.
We have not seen such a cut-point in any of the more than
70 other trials of antifungal therapy we have reviewed [1-
4,8], and in a later study of caspofungin, the same first
author now used a 48-hour cut-point for the same out-
come, in the same journal, and again without any justifi-
cation or explanation [9].
We believe the use of arbitrary cut-points creates bias.
When we included baseline infections that persisted
despite treatment, we found 15 vs. 23 infections (P =
0.27) [4], whereas the trial report noted 8 versus 21 infec-
tions (P = 0.02) [5]. Our analysis is not only unbiased, it
is also the clinically relevant one, as patients with baseline
infections are part of the clinical reality when patients are
treated on suspicion of a fungal infection.
The abstract was highly misleading. Despite the fact that
voriconazole was clearly inferior to amphothericin B, it
concluded that "Voriconazole is a suitable alternative to
amphothericin B preparations" and referred to "break-
through" fungal infections and a significant difference in
nephrotoxicity, arbitrarily defined as a 1.5-fold increase of
baseline s-creatinine values, which disappeared com-
pletely when the usual definition of a 2-fold increase was
used [5]. Twenty-nine versus 32 patients had a 2-fold
increase, whereas 43 versus 80 patients experienced a 1.5-
fold increase (P < 0.001).
The second trial was flawed by design. It compared vori-
conazole to amphothericin B deoxycholate in the treat-
ment of invasive Aspergillus infections [6]. The
deoxycholate preparation was used without requirements
for pre-medication, which is generally advised to reduce
infusion-related toxicity, or substitution with electrolytes
and fluid as advised to reduce nephrotoxicity, which can
be practically abolished by this precaution [10,11]. These
omissions are particularly disturbing considering that the
planned duration of treatment was 84 days. Voriconazole
was given for 77 days on average, but the comparator for
only 10 days, which precludes a meaningful comparison
of the two drugs.
References to the flawed trials
Both trial reports have been extensively quoted. As of 23
November 2005, the paper by Walsh et al. had been
quoted 192 times and the paper by Herbrecht et al. 344
times [12]. We selected randomly 50 articles of any type,
e.g. research reports, reviews, editorials and letters, that
quoted a trial report (25 for each report) to elucidate
whether the quotations reflected uncritically the main
conclusions of the trial reports. Two articles that were
coincidentally selected for both groups were replaced by
the next on the randomisation list (see final list in the
Additional file 1). We also looked at conflicts of interest,
defined as being author of one of the quoted trial reports;
being a Pfizer employee; being a consultant, speaker or on
the advisory board for Pfizer; or being author of an article
with no declaration of conflicts of interest, but having
declared a conflict of interest related to Pfizer in another
of the included articles.
Two authors independently evaluated each article and dif-
ferences were settled by discussion. We excluded 10 arti-
cles that quoted Walsh et al. and 7 articles quoting
Herbrecht et al. as they did not refer to any of the main
conclusions, but to minor issues, e.g. hepatotoxicity.
Five of the 15 included articles that quoted Walsh et al.
accepted their main conclusion whereas 7 noted that non-
inferiority had not been demonstrated. Seven articles
mentioned the confidence interval by Walsh et al.,
whereas only one article referred to the confidence inter-
val published by the FDA. Six articles noted that voricona-
zole led to fewer break-through infections whereas oneTrials 2006, 7:3 http://www.trialsjournal.com/content/7/1/3
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noted that this was not a protocol-defined successful out-
come and another mentioned problems with the multi-
plicity of outcomes without allowance for multiple testing
as also noted by the FDA. Two articles claimed that vori-
conazole had less nephrotoxicity whereas one noted that
the proportions that had a doubling in serum creatinine
was similar. Only 3 articles had authors with a conflict of
interest, and only one criticism was raised in these.
None of the 18 included articles that quoted Herbrecht et
al. raised any criticism of the design of this trial and only
one mentioned that concerns had been raised about "dif-
fering durations of therapy, as well as the possibility of
excessive interruptions in the amphotericin arm", but the
authors went on to say, in the next sentence, that: "the
conclusion that voriconazole is superior to amphotericin
B for treatment of invasive aspergillosis has been wel-
comed by most clinicians" [13]. Eleven articles had
authors with a conflict of interest.
Discussion
We believe the available evidence cannot support a rec-
ommendation to use voriconazole instead of amphoth-
ericin B in immune-suppressed cancer patients as
amphothericin B given under optimal circumstances was
significantly better than voriconazole.
The authors of both trial reports nevertheless drew posi-
tive conclusions about voriconazole. Such positive but
unwarranted conclusions can be very useful for the spon-
sor's marketing department, in particular when published
in a prestigious journal with a high impact factor. Journals
that allow publication of misleading papers and conclu-
sions of industry-sponsored trials also benefit. First, the
income from reprints can be very large [14]. Second, drug
companies may orchestrate a large series of ghost-written
papers [15] that quote the favourable conclusions. This
practice may boost the journal's impact factor further,
adding to the journal's high reputation, but in reality
watering down the impact factor as a measure of quality
and reliability.
We found that the unwarranted conclusions were mostly
uncritically propagated in subsequent articles. It was par-
ticularly surprising that the relevant criticism raised by the
FDA was only quoted once, and that none of the articles
that quoted the trial report by Herbrect et al. noted the
obvious flaws in the design of this trial. We can only guess
what the reasons are for this, but wish to point out that the
number of authors with conflicts of interest we identified
is likely to be a gross underestimate. This is supported by
the fact that The New England Journal of Medicine during
two years had been able to solicit and publish only one
Drug Therapy article on a novel form of treatment after
the journal had introduced a policy that authors of
reviews and editorials would not have any financial inter-
est in a company (or its competitor) that makes a product
discussed in the article [16]. The journal has therefore
changed the policy to "any significant financial interest".
We believe it is a problem for health care that references
to flawed research can be so uncritical as we demonstrated
and suggest further research in this area. Other problems
with references are that they often predominantly select
those previous articles that had the most favourable find-
ings [17-19] or conclusions [19,20], or they exaggerate or
distort findings [19].
Conclusion
We agree with the former editor of the British Medical
Journal that medical journals can serve as an extension of
the marketing arm of the pharmaceutical industry [14].
This is difficult to avoid, even for prestigious journals with
careful peer review. However, it should be relatively easy
to ensure that the abstract reflects fairly on the remainder
of the paper, which is currently often not the case [21,22].
Furthermore, journals should not have any time limit for
accepting letters that point out serious weaknesses in a
study that have not been noted before [23].
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